Ebola Vaccine Market is a viral hemorrhagic fever caused by the Ebola virus. It is a life-threatening disease that is transmitted from animals to people. One of the most common ways for this virus to spread is by direct contact with an infected person's bodily fluids. Ebola illness symptoms include high fever, vomiting, sore throat, diarrhea, headache, and muscular pain, as well as internal and external bleeding in a few cases. Although there is no cure for Ebola virus sickness, symptomatic treatment such as electrolyte balance, imaging needed oxygen levels, and treating infectious conditions may aid in the patient's recovery. The majority of vaccines to prevent Ebola virus sickness are in various stages of development.
The rising number of Ebola Vaccine Market cases in afflicted areas, as well as the development of new vaccines, are projected to propel the market forward.
Increased mortality rates as a result of Ebola are projected to be a major driver of market expansion. According to the World Health Organization, over half of those infected with EVD died in January 2018. Ebola Vaccine Market was found in Siberia, Sierra Leone, Guinea, the Democratic Republic of Congo, Senegal, and Mali, as well as Nigeria. In the years 2014–16, outbreaks in West African nations such as Siberia, Liberia, and Guinea claimed the lives of approximately 11,300 people. During the 2014–16 outbreak, several cases were reported in the United States, Spain, Italy, and the United Kingdom among people who traveled to impacted African nations and people who came into contact with infected patients.
In a phase three trial published in The Lancet in December 2016, the rVSV-ZEBOV vaccine, also known as V920, developed jointly by Newlink Genetics and Merck & Company, was found to be effective in protecting against EVD. The Zaire Ebola virus strain is used in rVSV-ZEBOV. Merck intends to submit a final marketing approval application for its EVD vaccine to the US Food and Drug Administration in 2018. In addition, it prepared 3,00,000 vaccinations in the event of a new epidemic in sensitive areas. Various prominent players are concentrating their efforts on developing EVD vaccines in order to increase their market share. For example, GlaxoSmithKline produced the CAd3-ZEBOV vaccine, which was examined by the National Institute of Allergy and Infectious Disease, which began phase three trials in February 2016.
GAVI (Global Vaccine Alliance) is an international organization that paid Merck & Company $5 million in 2016 for vaccine procurement (V 920 vaccine). Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc. are all major competitors in the global Ebola vaccine market.
0 Comments